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Conclusion: The observed and predicted dose-effect of grade 
≥2 esophagitis were almost identical. This implies that our 
esophagus dose parameter accurately predicts toxicity for 
our current patient population and treatment protocol. This 
result is surprising, since esophagitis incidence was expected 
to decrease because of the introduced pre-hydration. While 
the origin of this discrepancy requires further investigation, 
it does show that the electronic toxicity scoring system and 
connection to the dose parameters appears to be a useful 
and valuable tool to audit the applicability of dose 
constraints in daily clinical practice. 
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Purpose or Objective: The radiosensitivity of cells has an 
oxygen dependence that leads to an undesired resistance of 
hypoxic tumour cells. This is well known[1] and the linear 
quadratic response model has been extended to account for 
it.[2] In order to properly model tumour responses, the 
information about the distribution of oxygen at a microscopic 
scale must be available.[3] Modelling works usually derive 
this distribution by solving the reaction-diffusion equation in 
a voxelized tumour geometry that includes a vascularization 
distribution model.[4] However, the oxygen available to the 
cells increases during radiotherapy due to, among other 
factors, cell killing. This reoxygenation process can turn 
hypoxic cells into oxic, changing the cells radiosensitivity 
during the treatment. In this work we implement two models 
of cell death kinetics, CDKM, to analyse how they affect 
reoxygenation and hence the response of tumours to 
radiotherapy. 
 
Material and Methods: Two CDKMs are compared:  
a) Delayed cell killing model, DCDKM: The number of dead 
cells after irradiation varies with time according to an 
exponential expression. Cells can die shortly or long after 
irradiation, mimicking early and late apoptosis.  
b) Instantaneous cell killing model, ICDKM: Cell death occurs 
immediately after irradiation (early apoptosis scenario).  
Using these models, oxygen distributions are recomputed 
before the delivery of each fraction, considering the 
decrease in oxygen consumption due to cell death caused 
during the previous fractions. The oxygen consumption can 
be computed globally, by voxel averaging surviving fractions, 
or locally, at a subvoxel scale. The differences in 
reoxygenation and tumour response arising under different 
CDKM and oxygen consumption scenarios depend on the 
vascular fraction, VF, and the fractionation scheme. This was 
illustrated for a conventional schedule and a 
hypofractionated treatment. 
 
Results: In the conventional treatment, the doses needed to 
achieve 50% tumour control (D50) are ~ 10 and 2 Gy larger 
under the ICDKM (for VFs of 1% and 3%, respectively). 
Differences are larger in the hypofractionated scheme, for 
which the TCP remains equal to zero under the DCDKM for a 
VF equal to 1%. For a VF equal to 3%, D50 values are ~ 20 Gy 
larger under the DCDKM. Similar results were found under the 
global and local oxygen consumption calculations. 
 
Conclusion: This work shows that the kinetics of cell death 
can have a great impact in the simulation of reoxygenation 
and tumour response. Radiation response models should 
account for cell death kinetics to properly evaluate tumour 
response, especially in hypofractionated schemes. 
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Purpose or Objective: The project aims at predicting tumor 
radiation starting from pre-treatment information related to 
cancer volume and oxygenation. 
 
Material and Methods: Eighteen Copenhagen rats, implanted 
with prostate tumor, underwent two irradiations (2x15Gy). 
Nine rats were treated in standard conditions (Air), while the 
remaining group (Oxy) inhaled oxygen. Before the first 
irradiation, an interleaved blood (BOLD) and tissue (TOLD) 
oxygen level dependent (IBT) MRI sequence was performed. 
Four indices were computed, namely, BOLD and TOLD signal 
intensity variation (dSI), and the change in longitudinal (dR1) 
and transverse (dR2*) relaxation rate. The tumor volume 
evolution was monitored by means of weekly caliper 
measurements. A two-equation system describing the 
uncontrolled growth and the response to treatment of the 
active cells population, along with the dead cell clearance 
dynamics, was implemented in Matlab® (MathWorks, Natick, 
Massachusetts, USA). Three parameters, namely the volume 
doubling time, the radiation sensitivity (α) and the dead cell 
clearance time, were learned on a subject-specific basis 
using a genetic algorithm. Finally, a feed forward neural 
network (FF-ANN) was trained (Fig. 1) to predict α starting 
from the MRI indices and initial volume, for each group 
(Air/Oxy). 
 
S804                                                                                                                                                  ESTRO 35 2016 
_____________________________________________________________________________________________________ 
 
Fig 1. FF-ANN scheme. 
 
Results: An inverse correlation of the radio-sensitivity 
parameter assessed by the model was found with respect the 
dR2* (-0.65) for the Oxy group. A further subdivision 
according to positive and negative values of dR2* showed a 
larger average radio-sensitivity for the Oxy rats with <0 and a 
significant difference in the two distributions according to 
the Wilcoxon-Mann-Whitney test (p<0.05). Finally, the 
Pearson correlation coefficient (R^2>0.9) revealed a strong 
agreement of the FF-ANN output with the target radio-
sensitivity. 
 
Conclusion: These preliminary findings support the 
hypothesis that the change in the R2* can be related to tumor 
oxygenation and, consequently, to its radio-sensitivity. In 
particular, the sign of the tendency is in accordance with the 
fact that an oxygenation increase reduces the tumor 
relaxation rate as reported in the literature. Moreover, the 
different distributions of α, outlined in the Oxy subgroups 
according to the dR2*, suggest that some subjects would 
benefit from oxygen inhalation more than others, reasonably 
due to their initial vascularization. Finally, the performance 
of the FF-ANN is promising, although it would require a larger 
dataset to validate its prediction ability. 
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Purpose or Objective: Administration of monoclonal 
antibody Epidermal Growth Factor Receptor (MoAb-EGFr) 
inhibitor every week during Radiotherapy (RT) of head and 
neck cancer (HNC) has shown improved outcomes as 
compared to RT alone in terms of locoregional disease 
control, progression free and overall survival, thanks to its 
radiosensitizing effect. MoAb-EGFr concentration varies day 
by day after injection, and radiosensitizing effect 
accordingly. A radiobiological (RB) model accounting for this 
variation (Pedicini, et al. Radiat Oncol. 2012;7:143) can be 
applied to shorten the treatment by optimizing daily RT dose, 
still maintaining unchanged the biological effect on the 
tumour (in terms of surviving cells) as compared to standard 
RT (7 weeks, PTV1: GTV, 70Gy; PTV2 = GTV+margin, 63Gy; 
PTV3: lymph nodes: 58.1Gy) and potentially reducing healthy 
tissue toxicity. In this study, such RB model was adopted in 
the clinical protocol FAMOSO (Frazionamento Accelerato 
MOdulato in SIB-IMRT dei tumori testa-collO) for the 
treatment of HNC tumours with simultaneous integrated 
boost (SIB), aiming to test the feasibility of accelerated 
modulated fractioning and to assess toxicity and response 
rate. 
 
Material and Methods: From literature data, showing that 
higher concentrations of MoAb-EGFr correspond to steeper 
tumor cell survival curves, radiobiological parameters were 
derived and included in the RB model to obtain the daily dose 
to be delivered to each target volume. To date, 2 of the 10 
expected pts (pt1: cT4cN1 oropharyngeal; pt2: cT2 cN3 
supraglottic squamous cell carcinoma) have been recruited 
and treated with SIB-IMRT with a curative intent. 
 
Results: The RB model suggested a 6 week treatment with 
daily increasing dose/fractions as follows: PTV1: 1.70, 1.95, 
2.15, 2.30, 2.35Gy; PTV2: 1.50, 1.75, 1.95, 2.05, 2.10Gy; 
PTV3: 1.40, 1.60, 1.80, 1.90, 1.95Gy. Both pts recruited in 
the FAMOSO protocol concluded the radiation treatment : pt1 
with no change of the planned schedule; pt2 with 
interruption of MoAb-EGFr after the 5th administration and, 
consequently, the last 10 RT fractions of RT were 
administered with standard fractionation. The total dose to 
the PTV1 were 62.7 and 61.8 Gy, respectively. Maximun 
acute skin and mucosal toxicity was G3. With a follow up of 6 
and 2 months, a partial response was obtained for pt1, while 
pt2 is still under evaluation. 
 
Conclusion: New treatment strategies, even accelerated, are 
feasible when combining RT with radiosensitizing drugs. The 
RB model is adequate to set up the treatment provided 
radiobiological parameters are available from clinical data. 
The preliminary clinical data of the protocol FAMOSO give 
encouraging results, suggesting that the treatment schedule 
is feasible with acceptable acute toxicity. Longer follow up is 
needed to confirm toxicity findings and assess response rate, 
and of course more patients have to be studied. 
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Purpose or Objective: Variability in the contouring of gross 
tumour and the derived planning target volumes (PTVs) 
between clinicians is well-known in radiotherapy. This study 
aims to quantify the impact of variability in contouring in 
terms of tumour control and normal tissue toxicity in Liver 
SBRT. 
 
Material and Methods: The National Radiotherapy Trials 
Quality Assurance (RTTQA) Group planning benchmark case 
for the ABC07 Trial was used (addition of stereotactic body 
radiotherapy to systemic chemotherapy in locally advanced 
biliary tract cancers; CRUK A18752, sponsor University 
College London). 12 centers performed contouring 
independently using radiotherapy trial protocol as per RTTQA 
pre-trial QA process. Each centre applied margins to derive 
PTV as per local practice. A standardised Volumetric 
Modulated Arc Therapy (VMAT) plan was produced based on 
gold standard contours and applied to all 12 sets of submitted 
contours aiming to deliver 50Gy in 5 fractions. However, due 
to large GTV this was unavoidably de-escalated to 40Gy to 
meet trial mandatory mean non-GTV Liver constraint. 
Tumour control was assessed through biologically effective 
dose (BED) to 98, 95 and 90% of the gold standard PTV. 65Gy 
BED, although disappointingly low for SBRT, was considered 
